Human tumor growth suppression by apoptosis induced with anti-ErbB-2 chimeric monoclonal antibody.
We established an anti-ErbB-2 mouse-human chimeric monoclonal antibody (MoAb), CH401, which was able to kill cancer cells overexpressing the ErbB-2 protein in vitro. The analysis of the killing mechanism indicated that MoAb CH401 might be the first anti-erbB-2 mouse-human chimeric MoAb which can induce the apoptosis of cancer cells, since morphological changes and DNA fragmentation were recognized in MoAb CH401-treated cells. The ErbB-2 receptor appears to have two opposing functions: acting as a receptor both for a growth factor and for an apoptotic factor. Our results indicate that MoAb CH401 treatment may prove to be very useful for cancer therapy.
Sasaki
S
S
First Department of Internal Medicine, Sapporo Medical University.
Tsujisaki
M
M
Jinnohara
T
T
Ishida
T
T
Sekiya
M
M
Adachi
M
M
Takahashi
S
S
Hinoda
Y
Y
Imai
K
K
D000818:Animals; D000911:Antibodies, Monoclonal; D017209:Apoptosis; D002453:Cell Cycle; D053938:DNA Fragmentation; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000378:metabolism* / Q000473:pathology; D010766:Phosphorylation; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology; D013997:Time Factors; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D011505:Protein-Tyrosine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins